Variables | Missing data | SC | MSD | p-value |
---|---|---|---|---|
SC/MSD | n = 172 | n = 69 | ||
Age, year | 0/0 | 51 [39–61] | 46 [34–64] | 0.722 |
Male—no. (%) | 0/1 | 108 (62.8) | 47 (68.1) | 0.528 |
Immunocompromised—no. (%) | 0/0 | 47 (27.3) | 14 (20.3) | 0.331 |
Onco-hematological malignancies—no. (%) | 0/0 | 23 (13.4) | 9 (13.0) | 1.000 |
Immunomodulatory treatment—no. (%) | 0/0 | 19 (11.0) | 3 (4.3) | 0.166 |
Other immunodepression—no. (%) | 0/0 | 7 (4.1) | 1 (1.4) | 0.529 |
Diabetes—no. (%) | 0/0 | 34 (19.8) | 7 (10.1) | 0.108 |
Artery disease—no. (%) | 0/0 | 3 (1.7) | 1 (1.4) | 1.000 |
Hypertension—no. (%) | 0/0 | 54 (31.4) | 11 (15.9) | 0.022 |
Period of admission | 0/0 | 0.610 | ||
< 2018—no. (%) | 112 (65.1) | 48 (69.5) | ||
2018–2021—no. (%) | 60 (34.9) | 21 (30.4) | ||
ARDS etiology | 0/0 | 0.032 | ||
Others—no. (%) | 82 (47.7) | 29 (42.0) | ||
Bacterial—no. (%) | 63 (36.6) | 19 (27.5) | ||
Viral—no. (%) | 27 (15.7) | 21 (30.4) | ||
MDRO colonization at admission—no. (%) | 6/0 | 22 (13.5) | 6 (8.7) | 0.420 |
ESBL-PE– no. (%) | 20 (90.9) | 4 (66.7) | ||
Carabapenem-resistant enterobacteriaceae—no. (%) | 1 (4.5) | 0 (0.0) | ||
Methicillin-resistant Staphylococcus aureus—no. (%) | 0 (0.0) | 1 (16.7) | ||
Imipenem-resistant Acinetobacter baumannii—no. (%) | 1 (4.5) | 0 (0.0) | ||
Multidrug-resistant Pseudomonas aeruginosa—no. (%) | 0 (0.0) | 1 (16.7) | ||
SOFA score at cannulation, | 2/0 | 14 [10–17] | 9 [7–11] | < 0.001 |
PaO2/FiO2 at cannulation, mmHg | 57/4 | 60 [54–78] | 72.40 [55.50–99.50] | 0.015 |
PaCO2 at cannulation, mmHg | 118/6 | 61 [48.25–77.50] | 51 [41–64.25] | 0.017 |
Lactate at cannulation, mmol/L | 143/14 | 5.30 [2.30–8.00] | 2.40 [1.50–3.25] | 0.005 |
Outcomes | ||||
ECMO-associated infection—no. (%) | 0/0 | 67 (39.0) | 13 (18.8) | 0.004 |
Ventilator-associated pneumonia—no. (%) | 0/0 | 58 (33.7) | 12 (17.4) | 0.018 |
Bloodstream infection—no. (%) | 0/0 | 31 (18.0) | 7 (10.1) | 0.186 |
Number of days with antimicrobial treatment, days | 0/10 | 13 [5–30] | 7 [2–10] | < 0.001 |
Number of days alive without antimicrobial treatment at day 60 | 0/10 | 27 [0–53] | 42 [8–53] | 0.009 |
Length of ECMO support, days | 0/3 | 7 [4–18] | 11 [5–24] | 0.234 |
Length of ICU stay, days | 60/1 | 22 [10–40] | 24 [15–42] | 0.427 |
MDRO colonization acquisition—no. (%) | 8/0 | 30 (18.3) | 2 (2.9) | 0.004 |
Death during ECMO support—no. (%) | 0/0 | 64 (37.2) | 26 (37.7) | 1.000 |
Death in ICU—no. (%) | 0/0 | 74 (43.0) | 31 (44.9) | 0.90 |